Skip to content
OpenCapital
Get started

Veradermics MANE Q4 2024 earnings

Reported March 30, 2026

Diluted EPS-$1.06Beat by $0.75
EPS estimate-$1.81

Next report

Aug 11, 2026 (In 4 weeks)
EPS estimate-$0.66

Financials

Q4 2024

Income statement

See full
Operating income-$6.7M—
Net income-$6.6M—
EPS (diluted)-$9.26—

Balance sheet

See full
Cash & equivalents$53.1M—
Total equity-$48.5M-118%
Total assets$55.5M—

Cash flow

See full
Operating cash flow-$5.9M—
CapEx-—
Free cash flow-$5.9M—

Versus estimates

Diluted EPS

Q1 2026-$1.32Miss by $0.76
Q4 2024-$1.06Beat by $0.75
Q4 2025-$1.63Beat by $0.19

Ask the moment Veradermics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Veradermics report Q4 2024 earnings?
Veradermics (MANE) reported Q4 2024 earnings on March 30, 2026.
What were Veradermics 's Q4 2024 revenue and EPS?
Veradermics reported diluted EPS of $-1.06 for Q4 2024.
Did Veradermics beat estimates in Q4 2024?
EPS beat the consensus estimate of $-1.81 by $0.75.
Where can I find Veradermics 's Q4 2024 SEC filings?
You can read the 8-K earnings release (0001827635-26-000010) directly on SEC EDGAR. The filing index links above go to sec.gov.